List of Excipients in Branded Drug PITAVASTATIN CALCIUM

Generic Drugs Containing PITAVASTATIN CALCIUM

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	pitavastatin	0378-5055	HYPROMELLOSE
Mylan Pharmaceuticals Inc	pitavastatin	0378-5055	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	pitavastatin	0378-5055	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
Mylan Pharmaceuticals Inc	pitavastatin	0378-5055	MAGNESIUM OXIDE
Mylan Pharmaceuticals Inc	pitavastatin	0378-5055	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	pitavastatin	0378-5055	POLYETHYLENE GLYCOL 400

What are the Most Frequently-Used Excipients in PITAVASTATIN CALCIUM?

# Of NDCs	Excipient
2	CALCIUM CARBONATE
2	CROSPOVIDONE
1	HYPROMELLOSE
3	HYPROMELLOSE 2910
2	HYPROMELLOSES
6	LACTOSE MONOHYDRATE

Pitavastatin Calcium Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Pitavastatin calcium is a mature, low-dose oral statin with broad generic availability and limited remaining protection from the active ingredient. Commercial value has shifted from basic tablet replication to differentiated formulations, pediatric usability, supply-chain optimization, and excipient-enabled performance. The strongest opportunities are immediate-release tablets with improved manufacturability, orally disintegrating or sprinkle-compatible products, and fixed-dose cardiovascular combinations. New products must preserve dose uniformity at 1 to 4 mg, control low-dose segregation risk, and avoid excipient changes that affect dissolution, stability, or bioequivalence.

What is the commercial status of pitavastatin calcium?

Pitavastatin calcium is the calcium salt of pitavastatin, an HMG-CoA reductase inhibitor marketed in the United States as Livalo. The FDA approved Livalo in 2009 for primary hyperlipidemia and mixed dyslipidemia. The labeling was later expanded to pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia, subject to labeled dosing and clinical conditions.[1]

Attribute	Commercial profile
Active ingredient	Pitavastatin calcium
Therapeutic class	HMG-CoA reductase inhibitor
Common strengths	1 mg, 2 mg, and 4 mg tablets
Administration	Once daily, with or without food
Reference product	Livalo
Originator	Kowa Pharmaceuticals America and related Kowa entities
FDA approval	2009
Current market	Generic and branded-generic competition
Biosimilar relevance	None; pitavastatin is a chemically synthesized small molecule
Main formulation	Immediate-release film-coated tablet
Key commercial constraint	Very low drug load and mature generic competition

Pitavastatin has a lower approved dose range than many statins. A 1 mg tablet may contain less than 1% active drug by weight, depending on the total tablet weight. That creates a process-control problem: excipient selection, geometric dilution, granulation behavior, and blend segregation can affect content uniformity more than the active ingredient’s absolute dose suggests.

What excipients are used in pitavastatin calcium tablets?

The Livalo immediate-release tablet uses a conventional direct-compression or dry-blending excipient architecture. FDA labeling identifies lactose monohydrate, low-substituted hydroxypropyl cellulose, hypromellose, magnesium aluminometasilicate, colloidal silicon dioxide, magnesium stearate, and film-coating components among the inactive ingredients.[1]

Core tablet excipient functions

Excipient category	Typical function in pitavastatin tablets	Strategic considerations
Lactose monohydrate	Diluent and compressibility aid	Can support low-dose dilution; requires control of moisture and reducing-sugar compatibility
Low-substituted hydroxypropyl cellulose	Disintegrant and binder contribution	Supports tablet breakup without creating a high-viscosity matrix
Hypromellose	Binder or film former	Useful for coating and mechanical integrity; grade selection affects processing
Magnesium aluminometasilicate	Adsorbent, glidant, and processing aid	May improve powder handling and reduce localized wetting or sticking
Colloidal silicon dioxide	Glidant and moisture-control aid	Important for flow but can increase dusting and complicate uniform distribution
Magnesium stearate	Lubricant	Overlubrication can slow dissolution and reduce tablet strength
Film-coat polymer	Protection, identification, swallowability	Coating weight and permeability can affect dissolution and stability
Titanium dioxide or iron oxides	Opacifier and colorant	Supports strength identification and light protection where needed

The formulation objective is not simply rapid disintegration. It is consistent dissolution, tablet robustness, and assay uniformity across commercial-scale batches. Pitavastatin calcium’s low dose makes blend uniformity and sampling strategy central development risks.

What is the best excipient strategy for pitavastatin calcium?

The most defensible strategy is a low-risk immediate-release platform based on a spray-dried or co-processed diluent, a controlled disintegrant system, a low-level glidant, and tightly managed lubrication.

1. Select the dilution system around low-dose uniformity

A formulation developer should evaluate lactose-based, microcrystalline-cellulose-based, mannitol-based, and co-processed filler systems. The objective is a narrow particle-size and density match between pitavastatin calcium and the principal diluent.

Lactose is commercially attractive because it is inexpensive, widely qualified, and present in the reference product. It may also improve tabletability at low active loading. However, lactose is a reducing sugar. Compatibility studies should examine assay and degradation under heat and humidity, particularly if the drug substance or formulation contains reactive functional groups.

Microcrystalline cellulose can improve compactibility and reduce dependence on lactose. Its drawbacks are higher sensitivity to moisture history, variable tablet ejection behavior, and potential differences in dissolution when the grade or moisture content changes.

Mannitol offers a nonreducing diluent option and can support orally disintegrating or chewable dosage forms. It is more expensive than lactose and may require a stronger binder or a co-processed grade to achieve adequate tensile strength.

2. Use a disintegrant system that does not delay release

Low-substituted hydroxypropyl cellulose is commercially logical because it is aligned with the reference product. Crospovidone, croscarmellose sodium, and sodium starch glycolate are alternative candidates.

Crospovidone can produce rapid wicking and is generally suitable for immediate-release products. Croscarmellose sodium provides swelling and wicking but may create dissolution variability if the grade, crosslinking, or compaction force changes. Sodium starch glycolate can provide strong swelling but may be more sensitive to overcompression and formulation water exposure.

For a generic tablet, the disintegrant should be screened against:

• 1 mg, 2 mg, and 4 mg strength proportionality;
• tablet hardness and friability;
• dissolution in multiple pH media;
• blend segregation during hopper discharge;
• stability at high humidity;
• interaction with magnesium stearate and film coating.

3. Control lubricant exposure

Magnesium stearate remains the practical default. It should be added late and blended for the minimum validated time. Excessive concentration or overmixing can produce hydrophobic particle surfaces, slower disintegration, and delayed dissolution.

Alternative lubricants such as sodium stearyl fumarate may reduce hydrophobicity and improve dissolution robustness. The tradeoff is supplier qualification, tablet ejection performance, cost, and regulatory familiarity. A lubricant change can be commercially useful when the development objective is a faster-dissolving or directly compressible formulation, but it rarely creates meaningful standalone IP.

4. Use glidants to solve a measurable processing problem

Colloidal silicon dioxide and magnesium aluminometasilicate can improve flow and reduce sticking. Their inclusion should be tied to powder-flow data, not treated as a default formula component.

The key process variables are:

• Hausner ratio and Carr index;
• blend uniformity after transfer;
• feeder consistency;
• segregation during scale-up;
• ejection force;
• tablet weight variation;
• content uniformity at the 1 mg strength.

A co-processed excipient can improve these parameters and support a manufacturing patent if the composition and process produce a demonstrated technical effect. The patent case is stronger when the product provides a measurable reduction in content-uniformity variability or compression defects.

What formulations are protected or commercially available for pitavastatin?

The core pitavastatin tablet is a mature immediate-release dosage form. The reference product’s formulation disclosures and FDA-approved labeling provide a benchmark for generic development, but they do not eliminate the need to establish pharmaceutical equivalence and bioequivalence.

Immediate-release film-coated tablets

This is the lowest-risk commercial segment. Generic manufacturers can use conventional excipients if the product meets the applicable quality and bioequivalence requirements. The commercial challenge is price competition and limited room for therapeutic differentiation.

Potential formulation improvements include:

• lower tablet mass;
• improved swallowability;
• color-coded strength identification;
• lactose-free or reduced-lactose versions;
• reduced coating weight;
• increased process capability for 1 mg tablets;
• packaging optimized for moisture protection.

Orally disintegrating tablets

An orally disintegrating tablet could address patients with dysphagia, older adults, and pediatric patients. Mannitol, crospovidone, microcrystalline cellulose, and low-moisture direct-compression excipients are likely platform candidates.

The product must control friability and mouthfeel while achieving rapid disintegration. A meaningful patent position would require more than substituting mannitol for lactose. It would need a defined excipient ratio, particle-size profile, manufacturing process, or performance result that is not an expected formulation adjustment.

Sprinkle or capsule-based dosage forms

A sprinkle product could target pediatric and swallowing-impaired patients. The principal technical risks are dose uniformity after opening, palatability, drug loss during administration, and stability after exposure to food or soft vehicles.

Multiparticulates may support this strategy, but they introduce additional manufacturing and bioequivalence complexity. A capsule containing coated granules or mini-tablets could be differentiated through taste masking and administration flexibility.

Chewable and liquid products

Liquid pitavastatin products face low-dose dosing accuracy, taste, chemical stability, and preservative-control challenges. A suspension may be more practical than a true solution if solubility is limited, but it requires sedimentation, redispersibility, syringe-delivery, and dose-uniformity data.

A pediatric liquid could create commercial differentiation because the FDA label includes pediatric use. The market opportunity is more specialized than for generic tablets, but the product may command higher margins if it solves administration problems without compromising exposure.

When did pitavastatin lose exclusivity?

Pitavastatin’s principal small-molecule exclusivity and early patent barriers have expired, and generic products are marketed in the United States. The major commercial protection for a new formulation would therefore arise from formulation, dosage-form, manufacturing, or method-of-use patents rather than the base active ingredient.

Protection category	Strategic status
Active ingredient protection	Expired or commercially exhausted
Original brand exclusivity	Expired
Immediate-release generic entry	Established
New formulation patents	Possible for differentiated products
Method-of-use patents	Narrow opportunity; must avoid overlap with known statin indications
Pediatric exclusivity	Historical regulatory protection, not a current barrier to ordinary generic entry
Biosimilar pathway	Not applicable

The FDA Orange Book remains the controlling source for listed patents and regulatory exclusivity associated with approved U.S. products.[2] Patent status should be reviewed by product, strength, dosage form, and listed patent use code rather than inferred from the active ingredient alone.

What is the Orange Book status of pitavastatin calcium?

The Orange Book identifies approved pitavastatin calcium products and any applicable listed patent information. Because generic pitavastatin products are approved and marketed, the original reference-product barriers do not prevent ordinary immediate-release generic entry.

For a new applicant, the relevant regulatory route is generally an abbreviated new drug application referencing the listed drug, provided the proposed product meets the applicable requirements for pharmaceutical equivalence, bioequivalence, labeling, manufacturing, and quality. A 505(b)(2) strategy may be more appropriate for a materially different dosage form, such as a liquid, orally disintegrating tablet, or modified administration system, depending on the product’s reliance on prior findings and the extent of new clinical or bridging data.[3]

Which companies are challenging or competing with Livalo?

Competition is divided between the originator product, authorized or branded generics, and independent generic manufacturers. The principal competitive factors are price, wholesaler access, manufacturing reliability, and formulary position.

Competitor type	Product strategy	Commercial pressure
Livalo	Branded reference product	Brand recognition and physician familiarity
Authorized generic or branded generic	Reference-like tablet	Price reduction with retained supply-chain familiarity
Large generic manufacturers	1 mg, 2 mg, 4 mg tablets	Lowest-cost and broad-distribution competition
Regional manufacturers	Selected strengths or markets	Supply flexibility and niche contracting
Differentiated developers	ODT, liquid, sprinkle, combination products	Higher margin but higher development risk

Paragraph IV litigation was most relevant during the initial generic-entry period. For present-day product strategy, the more material risks are manufacturing patents, formulation patents, labeling restrictions, and regulatory deficiencies. A new applicant should also assess whether any method-of-use patent creates an ANDA certification or labeling issue, even when the composition patent has expired.

How strong is the pitavastatin patent estate?

The base patent estate is weak as a barrier to conventional generic tablets because the active ingredient and original product protections are mature. The stronger opportunity lies in narrow, product-specific protection.

Potentially patentable formulation features

A defensible patent program could focus on:

• a low-dose blend that reduces content-uniformity variation;
• a defined co-processed excipient system;
• a lactose-free formulation with equivalent or improved dissolution;
• an ODT with defined disintegration and friability performance;
• taste-masked multiparticulates for pediatric use;
• a stable aqueous suspension;
• a process that reduces pitavastatin degradation under humidity;
• a tablet-coating system that improves light or moisture stability;
• a fixed-dose combination with another cardiovascular agent.

Patent strength depends on claim breadth, unexpected performance, comparative data, and freedom-to-operate analysis. A claim covering “pitavastatin calcium and a disintegrant” would likely be vulnerable if it merely recites routine formulation practice. A claim tied to a specific excipient ratio, particle-size distribution, process parameter, and superior result has a stronger probability of surviving obviousness scrutiny.

What generic launch risks exist for pitavastatin calcium?

Generic launch risk is moderate for the conventional tablet and higher for differentiated dosage forms.

Immediate-release tablet risks

The principal risks are:

1. Low-dose content uniformity, particularly at 1 mg.
2. Dissolution mismatch caused by lubricant level, compression force, or excipient grade.
3. Blend segregation during scale-up and packaging.
4. Stability failures involving moisture, heat, or light.
5. Strength proportionality problems across 1 mg, 2 mg, and 4 mg products.
6. Manufacturing-cost disadvantage against established suppliers.

ODT, liquid, and sprinkle risks

These products face added risks in:

• in vitro and in vivo bridging;
• dose delivery after administration with food or soft vehicles;
• taste masking;
• container-closure integrity;
• preservative effectiveness;
• microbial control;
• patient-use instructions;
• pediatric acceptability.

A differentiated product should be designed around a specific unmet administration need. A reformulation that adds excipient complexity without improving adherence, dosing accuracy, or manufacturing performance is unlikely to justify development cost.

What manufacturing and excipient opportunities exist?

Excipient suppliers can capture value in three ways: qualified substitution, platform formulation, and technical-service support.

Qualified excipient substitution

A supplier can target replacement of reference-product excipients with:

• directly compressible lactose;
• spray-dried lactose;
• co-processed cellulose-based fillers;
• low-moisture mannitol;
• high-functionality crospovidone;
• low-peroxide povidone or polymer systems;
• lower-hydrophobicity lubricants.

The commercial proposition must include scale-up data, compaction profiles, dissolution equivalence, and stability support. Price alone is weak because pitavastatin tablets use small quantities of active ingredient and face generic pricing pressure.

Platform formulation licensing

A ready-to-file formulation platform could include:

• composition and process specifications;
• blend-uniformity data;
• pilot-scale compression results;
• dissolution profiles;
• accelerated and long-term stability;
• excipient supplier qualification;
• regulatory justification for excipient selection.

Licensing value is higher for pediatric liquids, ODTs, and sprinkle products than for a standard film-coated tablet.

Combination-product opportunity

Pitavastatin can be evaluated in fixed-dose combinations with antihypertensive or diabetes therapies. Combination products may improve adherence and create new formulation claims, but they require compatibility work and can face separate patent estates around the partner active ingredient.

The commercial potential is strongest where the combination aligns with an established treatment pathway and reduces pill burden. The regulatory strategy must account for dosage-form compatibility, each active ingredient’s dose-response relationship, and the reference products used for approval.

How does pitavastatin compare with other statins for excipient commercialization?

Pitavastatin is attractive for excipient innovation because its dose is low and its tablet is relatively simple, but that same low dose raises uniformity risk. Atorvastatin and rosuvastatin have larger generic markets, while simvastatin and pravastatin have longer-established generic supply chains.

Factor	Pitavastatin	Atorvastatin	Rosuvastatin
Generic market maturity	High	Very high	Very high
Typical dose burden	Low	Moderate	Low to moderate
Low-dose uniformity risk	High	Moderate	High
Pediatric formulation opportunity	Meaningful	Meaningful	More limited by product positioning
ODT/liquid differentiation	Feasible	Feasible	Feasible
Price pressure	High	Very high	Very high
Excipient platform value	Moderate	Moderate	Moderate
Combination-product potential	High	High	High

Pitavastatin’s commercial differentiation is more likely to come from usability and manufacturing robustness than from a simple substitute excipient in a conventional tablet.

What revenue exposure and launch scenarios should investors assess?

Pitavastatin revenue is exposed to generic erosion, payer substitution, and the availability of competing statins. A conventional generic tablet is a volume business with limited pricing power. A differentiated formulation can improve margin, but market size is smaller and development costs are higher.

Launch scenario	Development burden	Margin potential	Primary risk
Conventional 1 mg/2 mg/4 mg tablet	Low to moderate	Low	Price compression
Lactose-free tablet	Moderate	Low to moderate	Weak differentiation
ODT	Moderate to high	Moderate	Bioequivalence and friability
Pediatric liquid	High	Moderate to high	Stability, taste, dosing accuracy
Sprinkle multiparticulate	High	Moderate to high	Administration and dose recovery
Fixed-dose combination	High	High if clinically aligned	Partner-product IP and regulatory complexity
Excipient platform license	Moderate	Moderate	Limited customer switching

A manufacturing or excipient supplier should prioritize products that can be used across multiple statins or low-dose cardiovascular drugs. A pitavastatin-only platform may not generate sufficient volume unless it supports a clear regulatory or manufacturing advantage.

Key Takeaways

• Pitavastatin calcium is a mature generic small molecule with no biosimilar issue.
• The base active-ingredient patent barrier is no longer the primary commercial constraint.
• Immediate-release tablets are technically manageable but highly price competitive.
• The central formulation problem is low-dose content uniformity, especially for 1 mg tablets.
• Lactose, low-substituted hydroxypropyl cellulose, hypromellose, magnesium aluminometasilicate, colloidal silicon dioxide, and magnesium stearate provide a practical reference formulation framework.
• Stronger commercial opportunities exist in ODT, pediatric liquid, sprinkle, and fixed-dose combination products.
• New formulation patents need defined compositions, processes, and comparative technical effects.
• Excipient suppliers should sell process capability, qualification support, and regulatory documentation rather than commodity materials alone.
• The most attractive near-term strategy is a robust low-dose immediate-release platform that can extend to other statins and cardiovascular products.

FAQs About Pitavastatin Calcium Excipient and Formulation Opportunities

Can pitavastatin calcium be formulated without lactose?

Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, and co-processed fillers can replace lactose, subject to compatibility, dissolution, content-uniformity, stability, and bioequivalence evaluation. A lactose-free product has commercial value only if it addresses a defined market or manufacturing need.

Is pitavastatin calcium suitable for an orally disintegrating tablet?

Yes. Its low dose is compatible with ODT development, but the formulation must manage blend uniformity, taste, friability, mouthfeel, and dissolution. Mannitol and crospovidone are practical screening candidates.

Does pitavastatin calcium need a biosimilar application?

No. Pitavastatin calcium is a chemically synthesized small molecule. Generic products use the abbreviated new drug application pathway when they reference an approved listed drug and meet applicable requirements.

Can an excipient combination create new pitavastatin patent protection?

Potentially, but routine substitution is unlikely to provide strong protection. A patent case is stronger when a defined excipient system produces unexpected improvements in content uniformity, dissolution, stability, compression, or patient administration.

Is a pitavastatin calcium liquid commercially attractive?

A liquid can address pediatric and swallowing-impaired patients, but it has higher development risk than a tablet. The key commercial requirements are accurate low-dose delivery, acceptable taste, chemical stability, microbial control, and a clear regulatory pathway.

References

1. U.S. Food and Drug Administration. (2023). Livalo (pitavastatin) tablets, prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Applications covered by Section 505(b)(2). FDA.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA.